These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Lobo CA; Dhar R; Kumar N Infect Immun; 1999 Apr; 67(4):1688-93. PubMed ID: 10085005 [TBL] [Abstract][Full Text] [Related]
25. Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25. Quakyi IA; Miller LH; Good MF; Ahlers JD; Isaacs SN; Nunberg JH; Houghten RA; Keister DB; Coligan JE; Moss B Pept Res; 1995; 8(6):335-44. PubMed ID: 8838417 [TBL] [Abstract][Full Text] [Related]
26. Poor CD4 Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S Front Immunol; 2021; 12():732667. PubMed ID: 34659219 [No Abstract] [Full Text] [Related]
27. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Kaslow DC; Bathurst IC; Lensen T; Ponnudurai T; Barr PJ; Keister DB Infect Immun; 1994 Dec; 62(12):5576-80. PubMed ID: 7960139 [TBL] [Abstract][Full Text] [Related]
28. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824 [TBL] [Abstract][Full Text] [Related]
30. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay. Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109 [TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674 [TBL] [Abstract][Full Text] [Related]
32. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Milek RL; Roeffen WF; Kocken CH; Jansen J; Kaan AM; Eling WM; Sauerwein RW; Konings RN Parasite Immunol; 1998 Aug; 20(8):377-85. PubMed ID: 9767603 [TBL] [Abstract][Full Text] [Related]
33. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907 [TBL] [Abstract][Full Text] [Related]
34. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245 [TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles. Lalitha PV; Biswas S; Pillai CR; Saxena RK Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786 [TBL] [Abstract][Full Text] [Related]
37. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016 [TBL] [Abstract][Full Text] [Related]
38. Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques. Datta D; Bansal GP; Grasperge B; Martin DS; Philipp M; Gerloff D; Ellefsen B; Hannaman D; Kumar N Vaccine; 2017 Dec; 35(50):7049-7056. PubMed ID: 29132995 [TBL] [Abstract][Full Text] [Related]
39. Transmission-blocking immunity against malaria and other vector-borne diseases. Kaslow DC Curr Opin Immunol; 1993 Aug; 5(4):557-65. PubMed ID: 8216932 [TBL] [Abstract][Full Text] [Related]
40. Immunization of Aotus monkeys with recombinant Plasmodium falciparum hybrid proteins does not reproducibly result in protection from malaria infection. Kocken CH; Hundt E; Knapp B; Brazel D; Enders B; Narum DL; Wubben JA; Thomas AW Infect Immun; 1998 Jan; 66(1):373-5. PubMed ID: 9423884 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]